<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02601690</url>
  </required_header>
  <id_info>
    <org_study_id>RES-010</org_study_id>
    <nct_id>NCT02601690</nct_id>
  </id_info>
  <brief_title>Observational Analysis of T Cell Responses to SPIREs for Multiple Allergens in Subjects With Allergy in North America</brief_title>
  <official_title>Observational, Cross-sectional Analysis of T Cell Responses to Synthetic Peptide Immuno-Regulatory Epitopes (SPIREs) for Multiple Allergens in Subjects With Allergy in North America</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adiga Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Circassia Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Adiga Life Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study intending to look at the response of a specific type of allergy&#xD;
      cells in the blood (called T cells) to a a type of immunotherapy product known as SPIREs&#xD;
      (Synthetic Peptide Immuno-Regulatory Epitopes), across a broad range of subjects. This is a&#xD;
      non-interventional study in which no investigational product will be administered to any&#xD;
      subject.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding&#xD;
  </why_stopped>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">June 25, 2017</completion_date>
  <primary_completion_date type="Actual">June 25, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of T cell responses to SPIREs</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of the distribution of allergen sensitivity across a broad range of common allergens</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">199</enrollment>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Blood Sampling</arm_group_label>
    <description>Participants allergic to one or more of cat, rye grass, ragweed or house dust mite.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood Sampling</intervention_name>
    <arm_group_label>Blood Sampling</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples for Peripheral Blood Mononuclear Cells (from whole blood), Immunoglobulin E&#xD;
      (from serum), and potential tissue typing (from whole blood).&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of subjects aged from 18 to 65 years, with a documented&#xD;
        history of allergy to one or more of the following: cat, short ragweed, Rye grass, or House&#xD;
        Dust Mite.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, aged 18-65 years.&#xD;
&#xD;
          2. Willing and able to provide written informed consent.&#xD;
&#xD;
          3. One year history of allergic rhinoconjunctivitis to one or more of cat, short ragweed,&#xD;
             Rye grass, or HDM.&#xD;
&#xD;
          4. Positive skin prick test to each allergen for which a subject has a qualifying&#xD;
             clinical history.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically relevant history of alcohol or drug abuse.&#xD;
&#xD;
          2. Use of any oral or parenteral (except low dose inhaled) corticosteroids within 2&#xD;
             months prior to the visit or any other immunosuppressive therapy within 3 months prior&#xD;
             to the visit.&#xD;
&#xD;
          3. Vaccination/ inoculation within the 6 weeks prior to the first visit.&#xD;
&#xD;
          4. A history of any significant disease or disorder (e.g. autoimmune, cardiovascular,&#xD;
             pulmonary, gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine,&#xD;
             metabolic, neoplastic/malignant, psychiatric, major physical impairment, severe atopic&#xD;
             dermatitis).&#xD;
&#xD;
          5. Subjects who have taken an investigational drug within 6 weeks prior to the visit or&#xD;
             are currently participating in any other clinical study.&#xD;
&#xD;
          6. Recent blood donation of an amount of &gt;100 mL.&#xD;
&#xD;
          7. Immunotherapy within the last 5 years to any of the allergens for which a subject&#xD;
             would otherwise be eligible on the basis of clinical history and skin prick test&#xD;
             result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Empire Clinical Research</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>O&amp;O Alpan</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 9, 2015</study_first_submitted>
  <study_first_submitted_qc>November 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2015</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rye Grass</keyword>
  <keyword>Ragweed</keyword>
  <keyword>Cat</keyword>
  <keyword>House Dust Mite</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

